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Abstract
Background: Widely accepted somatic mutation theory of carcinogenesis states that mutations
in oncogenes and tumor suppressor genes in genomes of somatic cells is the cause of neoplastic
transformation. Identifying frequent mutations in cancer cells suggests the involvement of mutant
genes in carcinogenesis.
Results: To develop an in vitro model for the analysis of genetic alterations associated with breast
carcinogenesis, we used random mutagenesis and selection of human non-tumorigenic
immortalized breast epithelial cells MCF-10A in tissue-culture conditions that mimic tumor
environment. Random mutations were generated in MCF-10A cells by cultivating them in a tissue-
culture medium containing the frameshift-inducing agent ICR191. The first selective condition we
used to transform MCF1-10A cells was cultivation in a medium containing mutagen at a
concentration that allowed cell replication despite p53 protein accumulation induced by mutagen
treatment. The second step of selection was either cell cultivation in a medium with reduced
growth-factor supply or in a medium that mimics a hypoxia condition or growing in soft agar. Using
mutagenesis and selection, we have generated several independently derived cultures with various
degrees of transformation. Gene Identification by Nonsense-mediated mRNA decay Inhibition
(GINI) analysis has identified the ICR191-induced frameshift mutations in the TP53, smoothelin, Ras
association (RalGDS/AF-6) domain family 6 (RASSF6) and other genes in the transformed MCF-10A
cells. The TP53 gene mutations resulting in the loss of protein expression had been found in all
independently transformed MCF-10A cultures, which form large progressively growing tumors
with sustained angiogenesis in nude mice.
Conclusion: Identifying genes containing bi-allelic ICR191-induced frameshift mutations in the
transformed MCF-10A cells generated by random mutagenesis and selection indicates putative
breast-tumor suppressors. This can provide a model for studying the role of mutant genes in breast
carcinogenesis.
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Background
It has been proposed that, even from its earliest stages,
cancer development is associated with DNA replication
stress, which leads to genomic instability and selective
pressure for p53 inactivation [1]. This hypothesis was
based on the fact of frequent inactivation of the p53 path-
way in human tumors and on a demonstration that
human early pre-cancerous lesions show signs of DNA
damage-response activation [1-4]. These observations
suggest that selection for cells that can tolerate DNA dam-
age-signaling in precancerous cells is likely to take place
during the early stages of tumor progression in vivo. We
hypothesized that an extended in vitro cultivation of
human immortalized cells in tissue culture conditions
that generate DNA damage response activation and create
selective pressure for p53 inactivation can result in tumor-
igenic cell transformation.
MCF-10A cells are frequently used as a normal control in
breast cancer studies [5-9]. These cells were derived from
the mammary tissue of a cystic fibrosis patient and have
normal mammary epithelial cell morphology. These cells
do not have mutations in the p53 gene but show
homozygous loss of the p16/p15 locus[10] and do not
form tumors in nude mice or colonies in semi-solid low
melting agarose. Similar to normal human breast epithe-
lial cells, at confluence the MCF-10A cells form dome
structures in tissue culture plates and produce mammary
spheres in 3D collagen culture. All of these characteristics
make MCF-10A cells a model of choice for breast tumor
progression studies.
The role of genomic instability in carcinogenesis is
thought to generate variability within the tumor cell pop-
ulation and to facilitate selection of genetic variants that
have growth advantages in the tumor environment. We
speculated that continuous chronic exposure of cells to
mutagens at concentrations that induce activation of the
DNA damage-response, although still allowing DNA rep-
lication and cell proliferation, would provide conditions
for both, mimicking genomic instability through the
increased rate of mutations and selecting genetic variants
that acquire tolerance to DNA damage-response activa-
tion. To mimic genomic instability and generate genetic
variability within populations of MCF-10A cells, we used
the acridine mutagen ICR191. This DNA-intercalating
chemical produces an insertion of one G:C base-pair in a
short poly-G:C repetitive DNA sequence[11]. We rational-
ized that frameshift mutations produced by ICR191 treat-
ment may cause the inactivation of tumor-suppressor
genes related to breast carcinogenesis and result in the
transformation of MCF-10A cells. Frameshift mutations,
which generate premature translation-termination
codons (TPC) located more than 25 base pairs upstream
of the last exon/exon junction, frequently initiate mutant-
mRNA degradation through the nonsense-mediated
mRNA decay (NMD) mechanism[12,13]. Thus, the
mutant gene can be identified in the transformed cells
using GINI analysis[14], as we have shown in prostate and
colon cancer cell lines [15,16]. Bi-allelic inactivation of a
gene in the transformed MCF10-A cultures may indicate a
potential tumor-suppressor gene related to breast carcino-
genesis.
Results
Transformation of MCF-10A cells using ICR191 treatment
Mutagenesis and selection was initiated in five parallel tis-
sue-culture plates seeded with 1 million MCF-10A cells in
each plate (subsequently referred to as MCF10Aα,
MCF10Aβ, MCF10Aγ, MCF10Aδ and MCF10Aε). As a
result, five independent sets of MCF-10A cultures with
various degrees of transformation were generated. Two
consecutive steps of in vitro selection were used to trans-
form the MCF-10A cells. The first selective step promoted
clonal expansion of cells that had acquired tolerance to
DNA damage-signaling which was achieved by cell culti-
vation in a complete medium containing 500 ng/ml of
ICR191. This concentration of drugs allowed cell prolifer-
ation despite the DNA damage-response activation mani-
fested as an increased level of TP53 protein, alterations in
cell-cycle progression and changes in cell morphology in
tissue culture, which was manifested as a slightly larger
cell size and more flat appearance (Figure 1A–C).
After six months of selection for the resistance to DNA
damage-signaling, all five cultures had a higher than con-
trol untreated cells rate of replication in the presence of
mutagen (not shown). Also, all five cultures had acquired
signs of cell transformation, such as the loss of contact
inhibition at high density and the ability to form growing
colonies in soft agar (Figures 2A and 2B). One culture
(MCF10Aε) has acquired a higher rate of cell proliferation
in the absence of mutagen (Figure 2C). Following subcu-
taneous injections of 5 million cells into the flanks of
nude mice, three out of five cultures (MCF10Aα,
MCF10Aγ and MCF10Aδ) produced small (~2 mm in
diameter) palpable tumors. These tumors were localized
at the site of inoculation for more than four months with-
out an increase in size.
The second step of selection used to isolate more aggres-
sive variants of the MCF-10A cells involved selection for
either the ability of anchorage-independent growth or the
ability to grow in a medium with either reduced growth-
factor supply or resistance to hypoxia. Selection for
anchorage-independent growth was applied to the
MCF10Aα and MCF10Aβ cultures. Cells from these cul-
tures had been cloned in soft agar and, after two weeks,
four of the fastest-growing colonies of MCF10Aα cells,
and one colony of MCF10Aβ cells, were isolated andMolecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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Effect of ICR191 exposure on MCF-10A cells Figure 1
Effect of ICR191 exposure on MCF-10A cells. A. Fluorescence-activated cell-sorting (FACS) analysis demonstrates that 
MCF-10A cells, after 24 hours of cultivation in a tissue-culture medium containing 500 ng/ml of ICR191, have an increased pro-
portion of cells arrested in the S and G1 phases of the cell cycle. B. Western blot demonstrates the accumulation of P53 pro-
tein induced by ICR191 treatment. C. A slightly larger size and flatter appearance of MCF-10A cells after 24 hours of exposure 
to 500 ng/ml of ICR191.Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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Transformation of cells selected for the ability to replicate under chronic exposure to ICR191 Figure 2
Transformation of cells selected for the ability to replicate under chronic exposure to ICR191. A. Loss of contact 
inhibition by the MCF-10A cells selected for DNA damage-resistance. Passage- matched control MCF-10A cells (left) and the 
cells from the MCF-10A alpha culture after six months of cultivation in the presence of ICR191 (right) were plated in the 
medium without carcinogens and allowed to grow until the state of confluence. The 3D structures formed by DNA damage-
resistant at the state of confluence cells are seen under a light microscope. B. Microscopically visualized colonies produced in 
three weeks in soft agar by the MCF10Aα cells selected for resistance to ICR191 (right) but not by the control passage-
matched MCF-10A cells (left). C. A higher rate of MCF10Aε cell-replication after cultivation for four months in the presence of 
ICR191. Passage-matched control MCF-10A cells and the cells from the MCF10Aα and MCF10Aε cultures after four months of 
cultivation in the presence of ICR191 were seeded in 30 mm plates in triplicate (5 × 104 cells per plate), and the cell numbers 
were counted at the indicated times using a hemocytometer. Standard errors were calculated on the basis of triplicate meas-
urements.Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
Page 5 of 12
(page number not for citation purposes)
Histological analyses of tumors produced by transformed MCF10A cells in nude mice Figure 3
Histological analyses of tumors produced by transformed MCF10A cells in nude mice. The first row from the top 
shows neovascularity in the peritumoral stroma of a large tumor formed by transformed MCF10A cells in nude mice.A. Posi-
tive immunoreactivity with anti-CD31 antibody (DAB chromagen) from tumors formed in nude mice by MCF10AβL cells 
selected for hypoxia resistance. B. Negative staining with a control IgG antibody. The second and third rows from the top 
show variable degrees of tumor differentiation by transformed MCF10A cells. C. H&E section of MCF10AαL tumor cells, 
which were selected for reduced growth factor supply shows focal clear cell change (*) with adjacent prominent ductal differ-
entiation (see arrows). D. H&E section of a tumor formed in a nude mouse by MCF10AαL cells selected for hypoxia resistance 
exhibit growth within desmoplastic stroma with central comedo-like tumor necrosis. E. H&E section of a tumor formed by the 
secondary inoculation of MCF10AαL cells selected for reduced growth factor supply shows an area of geographic necrosis (*) 
with adjacent clear cell change (arrow) and nested growth of pleomorphic cells. F. H&E section of another tumor formed by 
secondary inoculation of MCF10AαL cells selected for reduced growth factor supply shows nested and strand-like growth of 
cells (*) within a desmoplastic stroma (arrows). The last row from the top shows the invasiveness of tumors formed by trans-
formed MCF10A cells. G. H&E section of a tumor formed by MCF10AαL shows that the tumor (*) begins to infiltrate into the 
adjacent skeletal muscle (arrow). H. H&E section shows that the pleomorphic carcinoma formed by the secondary injection of 
MCF10AβL cells selected for resistance to hypoxia grows within angiogenic stroma with vascular dilation and inflammation. All 
tissue was formalin-fixed and paraffin embedded. All images are at 20× original magnification.Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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Spectral karyotyping and array comparative genomic hybridization analyses of transformed MCF-10A cells derived from large  tumors grown in nude mice Figure 4
Spectral karyotyping and array comparative genomic hybridization analyses of transformed MCF-10A cells 
derived from large tumors grown in nude mice. A. SKY analysis of control MCF-10A and transformed MCF10AαL cells. 
*sign shows chromosomal alterations between control and transformed cells. B. Array CGH of MCf10AαL cells hybridized 
against control MCF-10A cells shows chromosomal alterations (indicated by arrows) correlated with those identified by SKY.Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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ICR191-induced frameshift mutations identified using inhibition of NMD and microarray analysis in the p53 and other genes in  the transformed MCF-10A cells Figure 5
ICR191-induced frameshift mutations identified using inhibition of NMD and microarray analysis in the p53 
and other genes in the transformed MCF-10A cells. A. Top: P53 gene-coding sequence with the frameshift mutations 
sites in different MCF-10A cultures underlined. Bottom: Sequence analysis shows heterozygous insertions of one cytosine 
within different short poly-C repeats in the coding DNA of p53 gene in MCF10Aγ and MCF10Aβ cells. In the MCF10Aβ cells, 
both mutations can be seen in the sequencing graph of a single PCR amplified fragment. The insertion of one C in the poly-C 
repeat located at 460–464 nucleotides of the fragment results in the appearance of double peaks on the sequencing graph. The 
second insertion in the poly-C repeat at nucleotides 512–517 of the second allele results in the disappearance of double peaks 
at the end of the sequencing graph. B. Western blotting analysis of p53 protein expression and accumulation in response to 
ICR191 exposure in different MCF-10A derivative cell-lines. Only those cell-lines with the loss of p53 expression could form 
large, progressively growing tumors in nude mice. C. Top: Sequencing graphs show the homozygous insertion of one C into 
the coding poly-C of the SMTN gene. (C)4 (mutant) and (C)3 (wild type) repeats can be seen on the sequences of SMTN gene 
from the MCF-10A and MCF10Aβ1 cells, respectively. Bottom: Sequencing graph shows the heterozygous insertion of one C 
into the coding poly-C repeat, which results in the appearance of double peaks at the end of the sequenced fragment of a 
RASSF6 gene in the MCF10Aα4 cells.Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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expanded in culture. After subcutaneous injections of 5
million of these cells into the flanks of nude mice, the soft
agar-derived clone of MCF10Aβ cells (MCF10Aβ1) pro-
duced a large (~1 cm in diameter), progressively growing
tumor four months after inoculation. Two soft agar-
derived clones from the MCF10α culture, MCF10α3 and
MCF10α4, produced large and small tumors, respectively.
After selecting for the ability to grow in the medium with
reduced growth-factor supply, two of the five cultures
(MCF10Aα and MCF10Aβ) acquired the ability to form
large, progressively growing tumors, and three cultures
(MCF10Aγ, MCF10Aδ and MCF10Aε) produced small
tumors four months after inoculation. After selecting for
resistance to hypoxia, three cultures (MCF10α, MCF10Aβ
and MCF10Aγ) produced large tumors, and the remaining
two cultures (MCF10δ and MCF10ε) produced small
tumors. Large tumors produced by transformed cultures
were shown to have undergone extreme angiogenesis (Fig-
ure 3A) and showed different degrees of differentiation
and invasiveness (Figure 3C–H).
Individual cell-lines were established from both large and
small tumors and expanded in culture. The names of cell-
lines derived from large and small tumors are subse-
quently denoted with the letters L and S, respectively.
Inoculations of cell-lines derived from large tumors
resulted in the formation of large tumors (1 cm in diame-
ter) in five out of five mice after one month. In contrast,
inoculations of cell-lines derived from the small tumors
produced either small tumors or none at all.
Spectral Karyotyping (SKY) and array comparative 
genomic hybridization of transformed cells shows minimal 
chromosomal instability
To identify chromosomal changes associated with the
transformation of MCF-10A cells, we compared the kary-
otype of the transformed MCF10AαL culture derived from
the tumor grown in nude mice with that of control MCF-
10A cells using SKY. Control MCF-10A cells are almost
diploid cells with several chromosomal abnormalities. All
MCF-10A cells from our lab have a reciprocal
t(3;9)(p14;p21) translocation and an unbalanced translo-
cation from chromosome 5q to the derivative 9[10]. Loss
of the p16 locus associated with t(3;9) translocation is
believed to contribute to the immortalization of MCF-10A
cells[17]. Also, a t(6;19)(p25;q12) rearrangement can be
seen in all control MCF-10A cells used in our lab (Figure
4A). In addition, trisomies of chromosomes 20 and 16, as
well as an additional structurally abnormal derivative of
chromosome 8, were present in all control MCF-10A cells.
Few additional chromosomal alterations have occurred in
the transformed cells. Figure 4A shows the duplication of
a 16q arm and the loss of one copy of a 16p arm in
MCF10AαL cells. The other alteration that has occurred in
transformed MCF10AαL cells was the loss of one copy of
chromosome 19. Also, one derivative, which includes the
translocation of chromosomes 9, 3 and 5, has been lost in
the transformed MCF10AαL. A comparison of MCF10AαL
cells versus control MCF-10A cells using array compara-
tive genomic hybridization (aCGH) has also identified
the duplication of 16q, the loss of part of 16p and the loss
of t(9;3;5) derivative in transformed cells (Figure 4B).
GINI analysis identifies ICR191-induced mutations in the 
transformed MCF-10A cells
To identify mutations that might have contributed to
MCF-10A cell-transformation, we used GINI analysis first
on the MCF10Aβ1 cells, as described in Material and
Methods. These cells, which were isolated from the colony
growing in soft agar, produce large, continuously growing
tumors in nude mice, indicating that breast cancer-related
tumor-suppressors could be mutated and selected during
transformation. Analyzing levels of mRNA transcripts in
the MCF10Aβ1 and control MCF1-10A cells using Affyme-
trix U133Plus2.0 GeneChips before and after inhibition
of NMD with emetine, we have selected 14 genes that sat-
isfied the requirements for candidates for sequencing
analysis (see Material and Methods). The candidates
included the genes coding for TP53, smoothelin (SMTN)
and ubiquitin specific peptidase 10 (USP10), which con-
tained insertions of one cytosine in short coding poly-
cytosine repeats, which are the characteristic mutations
induced by ICR191. The TP53 gene in the MCF10Aβ1 cells
contained two heterozygous mutations, resulting in the
absence of p53 protein expression (Figure 5A), while the
SMTN (Figure 5C) and UPS10 (not shown) genes had
homozygous and heterozygous mutations, respectively.
The TP53 gene is known to be frequently mutated in more
than half of all human cancers, including breast cancer.
Since the TP53 gene is the main regulator of DNA dam-
age-response[18] and the transformed derivatives of MCF-
10A cells had been selected for the ability to replicate
despite DNA damage-response activation, we analyzed all
the transformed MCF-10A cultures for the mutations in
the p53 gene. We found that all MCF-10A cultures that
can produce large, continuously growing tumors in nude
mice contained p53 gene mutations. The MCF10AγL cul-
ture had two heterozygous mutations that were different
from those in the MCF10β1 cells (Figure 5A), and the
MCF10AαL culture had one heterozygous mutation that
was identical to one mutation found in the MCF10 β1
cells. Although the mutation had been identified only in
one allele, the MCF10AαL cells, similarly to the
MCF10AγL and MCF10β1, do not express p53 protein
(Figure 5B). The DNA sequencing analysis of the p53 gene
in MCF10Aα3 and MCF10Aα4 cells generated from soft
agar growing clones has identified the mutation identical
to that in MCF10AαL cells. Western blot analysis hasMolecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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shown that MCF10Aα3 cells, which can produce large
tumors after inoculations into nude mice, do not express
p53 protein, while the MCF10Aα4, which cannot produce
large tumors, do. Similarly, MCF10Aδ and MCF10Aε cul-
tures, which, after all rounds of selection, could form only
small tumors in nude mice, had a wild-type allele of the
p53 gene and showed p53 protein-accumulation in
response to treatment with ICR191 (Figure 5B). On the
other hand, the MCF10AγS cells, which do not express
p53 protein due to mutations identical to that in
MCF10AγL cells, did not produce large tumors in nude
mice, suggesting that p53 inactivation was necessary but
not sufficient for in vivo tumor growth.
In contrast to the p53 gene mutations, the mutation in the
SMTN gene had been found only in the MCF10Aβ1 cells.
All other transformed MCF-10A cultures, including the
related MCF10AβL cell-line derived from a large tumor
produced by MCF10Aβ cells selected for resistance to
hypoxia, contained wild-type alleles of this gene. To iden-
tify other genes mutated in the process of in vitro transfor-
mation, we analyzed, using GINI, the MCF10Aα4 and
MCF10αL cultures. Sequencing of selected candidate
genes has identified heterozygous frameshift mutations in
the Ras association (RalGDS/AF-6) domain family 6
(RASSF6) (Figure 5C) in the MCF10Aα4 cells and in the
kinesin family member 22 (KIF22) in the MCF10αL cells.
Discussion
It has been hypothesized that the selection of genetic or
epigenetic DNA alterations, which provide growth/sur-
vival advantages to somatic cells in the context of the
tumor environment, is the driving force for tumor pro-
gression. We have demonstrated that the simulation of
Darwinian evolution in vitro by generating random muta-
tions and selecting in tissue-culture conditions that mimic
the tumor environment can result in the tumorigenic
transformation of non-tumorigenic cells. Due to the sto-
chastic nature of mutations, all the transformed cultures
of the MCF-10A cells had various degrees of tumorigenic-
ity. Only three out of five cultures, which had been sub-
jected to random mutagenesis and selection, have
acquired the ability to form large, continuously growing
tumors with sustained angiogenesis in nude mice, despite
the fact that all five cultures were treated identically. All
three cultures had gained inactivating mutations in the
TP53 gene, resulting in the loss of protein expression.
TP53 gene mutations identified in the transformed
MCF10AαL, MCF10AβL and MCF10AγL cells derived
from tumors growing in nude mice were identical to the
mutations identified in the corresponding cultures
derived after in vitro selection either for resistance to
hypoxia or to reduced growth-factor supply, or after selec-
tion for growth in soft agar. This result suggests that in
each transformed culture TP53-inactivating mutations
had occurred during the first round of selection when cells
were cultivated in the presence of ICR191, and that the
progenitors of rare cells that had acquired TP53 gene
mutations underwent clonal expansion during the second
round of selection in tissue-culture conditions that simu-
lated tumor environment.
ICR191-induced frameshift mutations generate prema-
ture translation termination codons (PTC), which fre-
quently initiate mutant mRNA degradations via  a
nonsense-mediated mRNA decay (NMD) pathway. Genes
mutated in the cells transformed by ICR191 exposure can
be identified using microarray-based analysis of mRNA
levels alterations induced by the inhibition of NMD in the
transformed as well as in the non-transformed control
cells. Identifying genes in the transformed cells containing
either inactivating mutations in both alleles or a mutation
in one allele accompanied by the loss of the second allele
can indicate potential tumor suppressors. Bi-allelic muta-
tions of the TP53 gene identified in the transformed
MCF10Aβ1 cells using NMD inhibition demonstrate the
proof-of-principle that our model of cell-transformation
by ICR191 exposure can be used for the identification of
breast tumor suppressors.
The RASS6 gene was the other known tumor-suppressor
gene that has been identified using NMD-inhibition to
contain frameshift mutation in the clone of transformed
MCF-10A cells derived from a colony growing in soft agar.
The expression of this gene has been shown to be down-
regulated in 30–60% of tumor-derived tissues from the
breast, colon, kidney, liver, rectum, pancreas, stomach
and thyroid gland compared to normal tissue [19]. Due to
mono-allelic occurrence in the transformed MCF-10A
cells, the mutation in the RASS6 gene, as well as the heter-
ozygous mutations in USP10 and KIF22 genes, can be pas-
senger mutations not relevant to cell transformation. We
cannot rule out the possibility, however, that haploinsuf-
ficiency caused by RASSF6 heterozygous mutation could
contribute to the survival of the MCF10Aα4 clone in soft
agar.
Smoothelin was the gene identified by NMD-inhibition to
contain homozygous ICR191-induced mutation in the
MCF10Aβ1 cells. The protein encoded by this gene associ-
ates with stress fibers and constitutes part of the cytoskel-
eton. Since the SMTN gene mutation has been identified
in a clone of MCF10Aβ cells selected for the ability to
grow in soft agar, inactivation of this gene could promote
anchorage-independent growth, a property of tumor cells
allowing them to grow in improper locations in vivo, a
characteristic that distinguishes malignant from benign
tumors[20]. Interestingly, SMTN gene mutations have
recently been identified in colorectal tumors, and the gene
has been suggested as a candidate colorectal cancerMolecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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gene[21]. We are planning to use MCF10Aβ1 cells, which
are null for the SMTN gene expression, as a model to study
the possible role of the gene in breast carcinogenesis.
Conclusion
We have demonstrated that by using NMD-inhibition and
microarray-based gene expression analysis we can identify
mutant genes in tumorigenic cells transformed by random
mutagenesis and selection. This strategy can be applied to
the identification of genes and pathways controlling par-
ticular traits of cell transformation. For example, similar
to identifying TPP53 gene mutations after selecting for
tolerance to DNA damage-response activation, GINI anal-
ysis of clones isolated after random mutagenesis and
selection of cells for resistance to chemotherapeutic drugs
can result in the identification of other genes controlling
response to chemotherapy. Also, our model of random
mutagenesis and selection can be used for microarray-
based monitoring of gene-expression alterations accom-
panying progression from almost normal to a trans-
formed phenotype of breast epithelial cells.
Methods
Cell-culture media and chemicals
The immortalized, non-transformed human mammary
epithelial cell-line, MCF-10A, was grown on standard tis-
sue-culture plastic in a 5% CO2-humidified incubator at
37°C in Complete MCF-10A Growth Medium composed
of DMEM/F12 (Mediatech, Inc., Herndon, VA) supple-
mented with 5% donor horse serum, 20 ng/ml epidermal
growth factor (EGF), 10 μg/ml insulin, 0.5 μg/ml hydro-
cortisone (Sigma, St. Louis, MO), 100 ng/ml cholera toxin
(Cambrex, Westborough, MA), and 100 units/ml penicil-
lin and 100 μg/ml streptomycin (Invitrogen, Carlsbad,
CA). A Growth Factor-Reduced MCF-10A Medium for the
second step of transformation and culturing transformed
clones was composed of DMEM/F12 supplemented with
5% donor horse serum (Sigma, St. Louis, MO) and 100
units/ml penicillin and 100 μg/ml streptomycin (Invitro-
gen, Carlsbad, CA), without the addition of supplements.
The acridine mutagen ICR191 (Sigma Chemical Co., St.
Louis, MO) was dissolved at 1 mg/mL in 0.01 M HCl and
was used as a stock solution before diluting in the tissue-
culture medium at 500 ng/ml concentration.
Transformation of MCF-10A cells using random 
mutagenesis and selection
Two steps of mutagenesis and selection had been used to
achieve the transformation of MCF-10A cells. The first
step of selection was for the ability to replicate despite
DNA damage-response activation. In this step, 1 million
MCF-10A cells were seeded in a 100 mm tissue-culture
plate and cultivated for six months in Complete MCF-10A
Growth Medium containing 500 ng/ml of ICR191. Dur-
ing this process, as cells reached confluence, they were
trypsinized, and half the cells were frozen in liquid nitro-
gen. The remaining cells were returned to the culture. In
the second step, cells were selected either for the ability to
grow in the medium with reduced growth-factor supply,
for the ability to grow in the hypoxic condition, or for
anchorage-independent growth. To select cells resistant to
a reduced growth-factor supply, cells were cultivated in
the Growth Factor-Reduced MCF-10A Medium contain-
ing 500 ng/ml of ICR191 for one to three months. To
select cells resistant to hypoxia, cells were cultivated in the
Complete MCF-10A Growth Medium containing 100 μM
of cobalt chloride, which is known to generate hypoxic
environment [22], and 500 ng/ml of ICR191 for one
month. To select for the ability for anchorage-independ-
ent growth, cells were challenged to grow in soft agar.
Soft-agar cloning
1 × 105 cells in Complete MCF-10A Growth Medium were
seeded into six-well plates with 2 ml 0.33% (w/v) low-
melting agarose, which was overlaid onto 2 ml of 0.6%
(w/v) agarose and fed every other day by exchanging 1.5
ml medium on top of the soft agar. Soft-agar cultures were
maintained at 37°C and observed microscopically for the
appearance of colonies. After three to four weeks in cul-
ture, the colonies were counted. In cases where cultures
were to be established from anchorage-independent colo-
nies, the top layer of low-melting agarose was plated into
tissue-culture dishes and kept in Complete MCF-10A
Growth Medium. Clones were picked using cloning cylin-
ders and developed into cell-lines.
Nude mice tumorigenicity assay
Cells in phosphate-buffered saline were mixed 1:1 with
Matrigel basement membrane matrix (BD Biosciences,
Franklin Lakes, NJ) and 3–4 × 106 cells in 100–150 μl
were injected subcutaneously into the flanks of 5-week-
old athymic female Ncr -nu/nu mice (National Cancer
Institute). The animals were maintained in accordance
with institutional guidelines at the Laboratory Animal
Facility at RPCI for six to eight months and palpated
weekly for tumor appearance. When tumor nodules
reached 1–2 cm in size, the mice were euthanized by
exposure to carbon dioxide. The tumors were excised and
divided into three pieces for developing into cell-lines to
be frozen for future microarray analysis, fixed in neutral
buffered formalin and embedded in paraffin for a routine
histological evaluation with 5 μm hematoxylin and eosin
(H&E) stained sections. Histological procedures were per-
formed at the RPCI Pathology Core Facility.
GINI analysis
Identifying mutant genes in the transformed MCF-10A
cells using inhibition of nonsense-mediated decay and
Affymetrix oligonucletide U133Plus2.0 GeneChip analy-Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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sis was performed as described previously for prostate
cells [16]. Briefly, control untransformed MCF-10A cells
and the MCF-10A transformed derivative cells were grown
in Complete MCF-10A Growth Medium until they
reached 70–80% of confluency. To inhibit NMD in cells,
emetine (100 μg/ml) was added to the tissue-culture
medium and, eight hours later, the total RNA was pre-
pared with TRIZOL reagents (Invitrogen, Carlsbad, CA)
according to manufacturer's specifications from emetine-
treated as well as untreated cells. The integrity and purity
of the total RNA were analyzed using a microfluidic elec-
trophoretic system (Agilent 2100 Bioanalyzer; Agilent
Technologies). RNA samples were processed and then
hybridized to Human Genome U133APlus2.0 GeneChip
(Affymetrix Inc, Santa Clara, CA), according to the manu-
facturer's instructions, by the Gene Expression Core facil-
ity at Roswell Park Cancer Institute. GeneChip expression
array analysis was performed using Affymetrix Microarray
Suite software, version 5 (GeneChip Analysis Suite). This
software uses two independent sets of algorithms, a quan-
titative algorithm (robust estimator of the mean differ-
ence in probe intensities) that computes the raw signal
and the SLR directly from the hybridization intensities of
the probes, as well as a confidence algorithm (non-para-
metric) that provides P-values to estimate the confidence
in detection (absent or present) or change (increase,
decrease or no change) of a specific target.
To select candidate genes out of hundreds genes that show
mRNA increase following emetine treatment in the trans-
formed cells for sequencing analysis, we used the follow-
ing cut-off criteria:1) the level of expression of a gene in
the emetine-untreated transformed cells had to be more
than threefold lower than that in emetine-untreated con-
trol MCF-10A cells; 2) the gene expression in control
untreated MCF-10A cells had to be detected as present; 3)
fold-change increase of mRNA level following emetine
treatment in the transformed cells had to be at least three-
fold higher than that in the untransformed control cells.
Sequencing analysis
One microgram of total RNA from emetine-treated trans-
formed MCF-10A cells was reverse transcribed using the
SuperScript II protocol (Invitrogen, Carlsbad, CA). Over-
lapping PCR primer sets were used to generate products
spanning entire open-reading frames for candidate genes.
Primers for sequencing analysis were designed using
Primer3 software available online [23]. To sequence the
p53 gene from genomic DNA, the sequences of p53 gene
exons with the flanking introns were retrieved from the
genomic databases, and the primers for PCR amplifica-
tion of genomic DNA fragments of p53 gene were
designed using Primer3 software. These are available
upon request. The PCR products were gel-purified and
sequenced using Applied Biosystems' PRISM 3100
Genetic Analyzer at the DNA Sequencing section of the
Biopolymer Facility at RPCI.
TP53 western blot analysis
Whole-cell extracts were prepared in a RIPA buffer, and
protein samples were denatured, separated by SDS/PAGE
gel, and transferred onto a Hybond-P nitrocellulose mem-
brane (Amersham Pharmacia) by using the MiniPRO-
TEAN 3 apparatus (Bio-Rad). Membranes were rinsed and
blocked with 0.05% Tween 20 (Sigma) and 1% skimmed
milk in PBS for one hour with three changes of this block-
ing buffer every 20 minutes at room temperature. Mem-
branes were then incubated with DO1 antibody
conjugated with horseredish peroxidase (Santa Cruz Bio-
technology, Santa Cruz) in a blocking buffer. After wash-
ing the membranes in blocking buffer for one hour with a
change of the buffer every 15 minutes at room tempera-
ture, membranes were visualized using ECL plus the West-
ern blotting detection system (Amersham Pharmacia).
The anti-actin monoclonal antibody (Sigma) was hybrid-
ized to membranes to serve as a measure of loading con-
trol.
Flow cytometry analysis
After rinsing with a phosphate-buffered saline solution,
the cells were trypsinized from culture dishes, rinsed with
PBS, fixed in 70% ice-cold ethanol, and stained with 10
μg/ml propidium iodide (PI) for 30 minutes. Flow cytom-
etry analysis was performed on the Coulter FACS analyzer
equipped with an air-cooled argon laser, producing 488
nm light in which fluorescence light-emission is collected
with a 620BP filter. An extended analysis of the DNA con-
tent and calculations of the percentage of cells in each
phase of the cell-cycle were performed on ModFit Lt soft-
ware (Verity Software House, Topsham, ME).
SKY Analysis
Cell cultures usually received treatments with Colcemid
(0.03–0.06  μg/ml). However, nocodazole (0.5 μg/ml)
was found to give the best results with some cells. Chro-
mosome spreads were prepared using air-drying methods.
After sequential digestion with RNase and pepsin accord-
ing to the procedure recommended by Applied Spectral
Imaging, Inc. (ASI: Vista, CA 92081), the chromosomal
DNA on the slides was denatured in 70% formamide and
then hybridized with a cocktail of human SKY paint
probes tagged with various nucleotide analogues (i.e., a
mixture of individual chromosome DNA prepared by
flow-sorting and PCR amplification)[24]. Thirty to 50
mitoses were chosen at random, and the images devel-
oped by combinations of five different flouorophores,
such as Rhodamine, Texas-Red, Cy5, FITC and Cy5.5,
were captured with a Spectral cube and Interferometer
module installed on a Nikon microscope. Spectra-Karyo-Molecular Cancer 2008, 7:51 http://www.molecular-cancer.com/content/7/1/51
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types were carried out using SKY View software (Version
1.62).
Array comparative genomic hybridization analysis
The preparation of Roswell Park Cancer Institute (RPCI)
custom CGH arrays using RPCI-11 BACs has been
described previously[25,26]. Briefly, the RPCI array con-
tains ~6,000 RPCI-11 BAC clones that provide an average
resolution across the genome of 420 kilobases. BACs were
printed in duplicate on amino-silanated glass slides
(Schott Nexterion, type A) using a MicroGrid ll TAS
arrayer (Apogent Discoveries, Hudson, NH) to generate
an array of ~12,000 elements. Genomic control MCF-10A
DNA and the transformed MCF10AαL DNA were fluores-
cently labeled by random priming and hybridized, as
described [25]. The hybridized slides were scanned using
a Genepix 4200A scanner (Axon, Inc., Union City, CA) to
generate high-resolution (10 μm) images for both Cy3
and Cy5 channels, and image analysis was performed
using ImaGene (version 4.1) software (BioDiscovery, Inc.,
El Segundo, CA).
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